Evotec Achieves Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi

Thursday, 27. October 2011 07:27
Evotec AG /
Evotec Achieves Two Milestones in Fragment-based Drug Discovery Alliance with
Shionogi
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany -27 October 2011: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced the achievement of specific success criteria in a
multiple target drug discovery collaboration with Shionogi & Co Ltd. and the
receipt of two milestone payments. Evotec and Shionogi will continue to
collaborate to progress the fragments through the drug discovery process.

The collaboration was initiated in October 2010 to identify small molecule
modulators of various protein-protein interaction targets selected by Shionogi.
Evotec has applied its proprietary and integrated fragment-based drug discovery
platform EVOlution(SM )to the selected targets. Active fragments have been
further characterised by X-ray crystallography to obtain structural information
to aid selection of the best fragment optimization strategy. A team of medicinal
chemists, biologists, computational chemists and structural biologists will in
close collaboration with Shionogi progress the molecules through the fragment to
lead and lead optimization stages.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are
extremely proud that we have reached our first project milestones with Shionogi.
This is further validation of our expertise and capabilities in fragment-based
drug discovery and we look forward to further supporting Shionogi in the
discovery of novel therapeutics."

No financial details are disclosed.

About EVOlution(SM)

EVOlution(SM) is Evotec's fragment-based drug discovery platform which combines
biochemical and biophysical techniques including nuclear magnetic resonance
(NMR), surface plasmon resonance (SPR) and X-ray crystallography for the
screening of low molecular weight compounds and characterization of the fragment
hits. By the combination of the orthogonal screening technologies, Evotec's
fragment screening platform is capable of screening a more diverse set of
biological targets than other fragment screening approaches, as well as being
able to screen the fragments in a high-throughput mode. The benefit of this is
the ability to identify active fragments for numerous classes of biological
targets in a short timeframe. For further information, please refer
to:www.evotec.com/fragment-based drug discovery.

About Fragment-based Drug Discovery

Fragment-based drug discovery (FBDD) is a drug discovery strategy that utilises
small molecules - fragments of more complex molecules - to generate efficient
starting points for drug discovery. This approach thus provides the opportunity
to effectively manage the molecular weight and overall complexity of drug
candidates, a recognised success factor in drug development.

Contact Evotec AG:

Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
werner.lanthaler@evotec.com

Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions or
circumstances on which any such statement is based.


--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


PDF_of_Press release:
http://hugin.info/131215/R/1558466/481524.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

[HUG#1558466]
Related Links: Evotec SE
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.